U.S. stocks opened lower, with the three major indices all declining slightly, including the Dow Jones Industrial Average down 0.33%, the S&P 500 down 0.15%, and the Nasdaq Composite down 0.13%. The weight-loss drug sector saw a key showdown result: Novo Nordisk (NVO.N) experienced a significant drop of 15.65% after its weight-loss drug Cagrisema's clinical trial data fell short of Eli Lilly's Zepbound; meanwhile, competitor Eli Lilly (LLY.N) opened strong, rising 3.86%.#Gate广场发帖领五万美金红包 $BTC